JP2024504822A - 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法 - Google Patents

出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法 Download PDF

Info

Publication number
JP2024504822A
JP2024504822A JP2023546211A JP2023546211A JP2024504822A JP 2024504822 A JP2024504822 A JP 2024504822A JP 2023546211 A JP2023546211 A JP 2023546211A JP 2023546211 A JP2023546211 A JP 2023546211A JP 2024504822 A JP2024504822 A JP 2024504822A
Authority
JP
Japan
Prior art keywords
csf
subject
cell
free
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504822A5 (https=
Inventor
ケヴィン・アカレット
トーマス・ジェンティネッタ
ラファエル・ブッツィ
ミヒャエル・ヒューゲルソファー
ドミニク・シャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
ZLB Bioplasma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZLB Bioplasma AG filed Critical ZLB Bioplasma AG
Publication of JP2024504822A publication Critical patent/JP2024504822A/ja
Publication of JP2024504822A5 publication Critical patent/JP2024504822A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
JP2023546211A 2021-02-01 2022-01-31 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法 Pending JP2024504822A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144043P 2021-02-01 2021-02-01
US63/144,043 2021-02-01
PCT/EP2022/052203 WO2022162218A1 (en) 2021-02-01 2022-01-31 Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke

Publications (2)

Publication Number Publication Date
JP2024504822A true JP2024504822A (ja) 2024-02-01
JP2024504822A5 JP2024504822A5 (https=) 2025-03-04

Family

ID=80739092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546211A Pending JP2024504822A (ja) 2021-02-01 2022-01-31 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法

Country Status (9)

Country Link
US (1) US20250339492A1 (https=)
EP (1) EP4284407A1 (https=)
JP (1) JP2024504822A (https=)
KR (1) KR20230142569A (https=)
CN (1) CN117136068A (https=)
AU (1) AU2022214388A1 (https=)
CA (1) CA3206884A1 (https=)
IL (1) IL304515A (https=)
WO (1) WO2022162218A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168750A1 (en) 2024-02-09 2025-08-14 Csl Behring Ag Haptoglobin for use in treating traumatic brain injury (tbi)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234195A1 (en) * 2019-05-17 2020-11-26 Universitaet Zuerich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137307A (en) 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
US4061735A (en) 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20060057065A1 (en) 2004-09-11 2006-03-16 Yanming Wang Composition and method to prevent and treat brain and spinal cord injuries
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
JP6370792B2 (ja) 2012-10-03 2018-08-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト タンパク質の精製方法
IL272167B2 (en) 2017-08-08 2024-02-01 Csl Behring Ag Hemopexin formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234195A1 (en) * 2019-05-17 2020-11-26 Universitaet Zuerich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J CEREB BLOOD FLOW METAB, vol. 38, no. 6, JPN6025049415, 2018, pages 1032 - 1046, ISSN: 0005744008 *
MOL NEUROBIOL, vol. 57, JPN6025049414, 2019, pages 159 - 178, ISSN: 0005744009 *
NAT REV NEUROL, vol. 14, JPN6025049412, 2018, pages 416 - 432, ISSN: 0005744006 *
NEUROSURG REV, vol. 43, JPN6025049411, 2019, pages 1273 - 1288, ISSN: 0005744005 *
WORLD NEUROSURG, vol. 120, JPN6025049413, 2018, pages 660 - 666, ISSN: 0005744007 *

Also Published As

Publication number Publication date
US20250339492A1 (en) 2025-11-06
CA3206884A1 (en) 2022-08-04
AU2022214388A1 (en) 2023-07-27
EP4284407A1 (en) 2023-12-06
IL304515A (en) 2023-09-01
WO2022162218A1 (en) 2022-08-04
CN117136068A (zh) 2023-11-28
AU2022214388A9 (en) 2024-07-11
KR20230142569A (ko) 2023-10-11

Similar Documents

Publication Publication Date Title
US11932676B2 (en) Recombinant klotho proteins and compositions and methods involving same
EP2941440B1 (en) Polymeric forms of h-nox proteins
US20200254075A1 (en) Methods and compositions for treating aging-associated conditions
Padmanabhan et al. Uromodulin, an emerging novel pathway for blood pressure regulation and hypertension
EP2707055B1 (en) Reducing soluble urokinase receptor in the circulation
JP7204030B2 (ja) 鎌状赤血球症における血管閉塞性クリーゼ、急性肺障害、および／または急性呼吸窮迫症候群を治療、改善および／または予防するためのａｄａｍｔｓ１３の使用
US20130123185A1 (en) Methods of treating and diagnosing acute chest syndrome
HK1258529A1 (zh) 用於治疗神经退行性和神经炎性病症的方法和组合物
US20220211808A1 (en) Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
JP2011516419A (ja) 鉄欠乏性障害を治療するためのフェリチンの使用
JP2024504822A (ja) 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法
US20130012443A1 (en) Methods of treatment of central nervous system hemorrhage using protoporphyrin ix-fe compounds
EA049722B1 (ru) Способ лечения или профилактики неблагоприятного вторичного неврологического исхода вследствие геморрагического инсульта
Ohtsuki et al. Is P‐glycoprotein Involved in Amyloid‐β Elimination Across the Blood–Brain Barrier in Alzheimer's Disease?
RU2818474C2 (ru) Гаптоглобин для применения в лечении неблагоприятного вторичного неврологического исхода после геморрагического инсульта
US20060216294A1 (en) Method of modulation
US20160375109A1 (en) Compositions and methods for treating intracerebral hemorrhage
WO2022155499A1 (en) Active delivery of radiotracers across the blood brain barrier
CN114206377A (zh) 重组adamts13治疗镰状细胞病的应用
US10947311B2 (en) VCAM-1 mediated methods and compositions for treating aging-associated impairments
US20250304655A1 (en) Expression System for Producing a Recombinant Haptoglobin (Hp) Beta Chain
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
WO2018088464A1 (ja) 脳梗塞の治療薬
HK1217499B (en) Polymeric forms of h-nox proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202